Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Recurrence × Trabectedin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 4 Ovarian Neoplasms 2 Liposarcoma 2 Leiomyosarcoma 2 Sarcoma, Synovial 1 Sarcoma, Alveolar Soft Part 1 Recurrence 1 Neurofibrosarcoma 1 Mesothelioma, Malignant 1 Malignant mesenchymal tumor 1 Ichthyosis, X-Linked 1 Histiocytoma, Malignant Fibrous 1 Hemangiosarcoma 1 Hemangiopericytoma, Malignant 1 Fibrosarcoma 1 Desmoplastic Small Round Cell Tumor 1 Chondrosarcoma, Extraskeletal Myxoid 1

Interventions

Cyclophosphamide 21 Dexamethasone 19 Rituximab 16 Cytarabine 16 fludarabine 10 Methotrexate 10 Gemcitabine 10 Bortezomib 10 Lenalidomide 9 Filgrastim 9 Etoposide 8 pembrolizumab 7 Vincristine 7 Paclitaxel 7 Cyclosporine 7 carfilzomib 6 Topotecan 6 Temozolomide 6 Docetaxel 6 Calcium Dobesilate 6 Antilymphocyte Serum 6 pomalidomide 5 fludarabine phosphate 5 Radiotherapy 5 Peripheral Blood Stem Cell Transplantation 5 Pemetrexed 5 Mitoxantrone 5 Granulocyte Colony-Stimulating Factor 5 Doxorubicin 5 Azacitidine 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03164980 2025-03-20

COMPASS

North Eastern German Society of Gynaecological Oncology

Phase 4 Terminated

89 enrolled 20 charts

Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡